Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease
- PMID: 9013406
- DOI: 10.1007/BF01271204
Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease
Abstract
Recently distorted chromatic contour perception has been demonstrated in Parkinson's disease (PD). The aim of our study is to determine the clinical factors which influence chromatic contour perception in PD. Chromatic and achromatic contour perception, colour discrimination and clinical data were evaluated in 73 patients with PD. We used a computer-aided method to determine the chromatic fusion time (CFT) which indicates the acuity of monochromatic contour perception. Chromatic CFT was generally shortened in patients as compared to controls (p < 0.01), whereas achromatic CFT was not significantly different. Variance analysis revealed the ability of colour discrimination and the risk of visual hallucinations as statistically significant (p < 0.05) variables influencing contour perception of certain stimuli. In contrast, disease stage, disease duration and disease severity have no relevant effect on chromatic contour perception in Parkinson's disease. On the basis of those properties one may suggest that distorted chromatic contour perception is due to an impairment at a central stage of visual processing in PD and an imbalance of the serotonergic system. Whether CFT is a reliable method to predict the individual risk of hallucinosis in PD has to be evaluated.
Similar articles
-
Alterations in chromatic contour perception in de novo parkinsonian patients.Eur Neurol. 1995;35(4):226-9. doi: 10.1159/000117133. Eur Neurol. 1995. PMID: 7671984
-
Disturbance of colour perception in Parkinson's disease.J Neural Transm Park Dis Dement Sect. 1993;6(1):11-5. doi: 10.1007/BF02252618. J Neural Transm Park Dis Dement Sect. 1993. PMID: 8216759
-
Chromatic and achromatic visual evoked potentials in Parkinson's disease.Electroencephalogr Clin Neurophysiol. 1996 Sep;100(5):443-7. Electroencephalogr Clin Neurophysiol. 1996. PMID: 8893662
-
Visual Dysfunction in Parkinson's Disease.Int Rev Neurobiol. 2017;134:921-946. doi: 10.1016/bs.irn.2017.04.007. Epub 2017 May 31. Int Rev Neurobiol. 2017. PMID: 28805589 Review.
-
Visual dysfunction in Parkinson's disease.Clin Neurosci. 1998;5(2):102-6. Clin Neurosci. 1998. PMID: 10785835 Review.
Cited by
-
Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.PLoS One. 2010 Dec 2;5(12):e14074. doi: 10.1371/journal.pone.0014074. PLoS One. 2010. PMID: 21152030 Free PMC article. Clinical Trial.
-
Ophthalmology issues in schizophrenia.Curr Psychiatry Rep. 2015 May;17(5):28. doi: 10.1007/s11920-015-0569-x. Curr Psychiatry Rep. 2015. PMID: 25773224 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical